Cyclosporine, low-density lipoprotein, and cholesterol

Mayo Clin Proc. 1988 Oct;63(10):1012-21. doi: 10.1016/s0025-6196(12)64916-7.


Lipoproteins are known to be able to transport a variety of drugs. This report suggests that low-density lipoprotein not only functions as an important carrier of cyclosporine in plasma but also facilitates transport of cyclosporine across the cell membrane by means of the low-density lipoprotein receptor. Such a mechanism would explain (1) the similar tissue distribution of cyclosporine and the low-density lipoprotein receptor, (2) the increase in immunosuppression and toxicity with low total serum cholesterol levels, and (3) the relative absence of immunosuppression and toxicity with high levels of cyclosporine in the blood in patients with hypertriglyceridemia. In addition to receptor-mediated uptake, a disturbance of the blood-brain barrier is suggested as an explanation of the high frequency of cyclosporine-induced central nervous system toxicity after liver transplantation. Cyclosporine-induced inhibition of the mitochondrial steroid 26-hydroxylase, an enzyme involved in the formation of bile acids from cholesterol and deficient in patients with cerebrotendinous xanthomatosis, may cause or contribute to the observed central nervous system toxicity. It also may explain the similar clinical features of cyclosporine-induced central nervous system toxicity and cerebrotendinous xanthomatosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Central Nervous System / drug effects
  • Cholesterol / blood*
  • Cyclosporins / adverse effects
  • Cyclosporins / pharmacokinetics*
  • Cyclosporins / pharmacology
  • Humans
  • Immunosuppression Therapy
  • Receptors, LDL / metabolism*
  • Tissue Distribution


  • Cyclosporins
  • Receptors, LDL
  • Cholesterol